Observational studyInternational ophthalmology2025
Pars plana vitrectomy with ILM peeling for macular edema of various etiologies: results from the SCRV macula surgery study.
Observational study in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate the outcome and complications associated with pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling in the treatment of macular edema of various etiologies.
methodsThis observational, multicenter, longitudinal, retrospective study, initiated by the Société Française de Chirurgie Rétino-Vitréene in 2022, involved 27 surgeons from all over France. Data were collected preoperatively and at multiple postoperative time periods up to two years. The etiologies of macular edema included epiretinal membrane (ERM), vitreomacular traction syndrome (VMT), diabetic macular edema (DME), retinal vein occlusion (RVO), and postsurgical cystoid macular edema (PCME).
resultsA total of 876 patients were included in the study. Best-corrected visual acuity (BCVA) significantly improved from 0.44 ± 0.26logMAR preoperatively to 0.22 ± 0.33logMAR at 1-2 years postoperatively (p < 0.001). Central macular thickness decreased from 422 ± 97 μm preoperatively to 337 ± 67 μm at 1-2 years. Intraoperative complications included retinal tear or retinal detachment in 6.3% of cases and intravitreal hemorrhage in 0.6% of cases. Postoperative retinal detachment occurred in 3.2% of patients. Intravitreal injection preoperatively was associated with poorer BCVA outcomes in the follow-up (p < 0.001). Patients who attained the best BCVA postoperatively demonstrated a macular thickness ranging from 320 to 400 μm.
conclusionPPV with ILM peeling proved to be an effective treatment for macular edema across various etiologies. Interestingly, good visual acuity following ILM peeling appeared to be associated with a larger macular thickness compared to the normal population. Intravitreal injections of anti-VEGF or dexamethasone implant preoperatively seemed to limit visual recovery.
Indexed as
Identifiers
40853490What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.